Electromedical Technologies and Nazarbayev University
Complete Agreement to Expand Promising
Joint Research
Programs
- Studies could lead to development of
next-generation targeted devices to effectively
treat chronic pain
- Stage I research programs designed
to study how electro-modulation communicates
to cells
- Program objective to decipher impacts of alternating
electrical fields on cell signaling and generating
cellular response
-Leveraging the executed agreement EMED
and Nazarbayev plan to begin the IDE
process with the FDA
SCOTTSDALE, AZ -- June
3, 2021 -- InvestorsHub NewsWire -- Electromedical Technologies,
Inc. (OTCQB:
EMED)
(the "Company"), a pioneer in the development and manufacturing of
bioelectronic devices, including the FDA cleared
WellnessPro Plus®, is pleased to announce that
the Company recently completed an
agreement with Nazarbayev University
to
expand
its
Stage I
collaborative
research
programs.
These Stage I programs will study how electro-modulation
communicates to cells by modifying intracellular signaling events
and altering physiological cellular
response.
Electro-modulation
therapies (electroceuticals)
are
conducted and widely applied in
medicine today utilizing a variety of
frequencies to reduce chronic pain.
A front page TIME
magazine article noted: "Electroceuticals
"are the next wave of new treatments we will have to treat
disease," says Kris
Famm, president of Galvani Bioelectronics,
a biotech collaboration between Glaxo-Smith-Kline and Google's
Verily that is focused on developing electricity-based
therapies (https://time.com/5709245/bioelectronic-medicine-treatments/).
Going forward,
researchers hope to learn how alternating electrical
fields affect cell physiology and induce their effects.
The main challenge is
to define specific electrical frequencies that alter cell
physiology by modulating the body's
cellular
signaling network. Deciphering the impacts of alternating
electrical fields on cell signaling will build a solid platform
for the development of novel
non-invasive technologies in medicine. Once this process is
unlocked, leading bioelectronic producers such as Electromedical
Technologies could develop new, highly effective, and
application/condition-specific devices for broad consumer
use.
Matthew Wolfson,
Founder and CEO of Electromedical Technologies, noted, "Unraveling the codes of
electro-modulation controlling cell behavior will be instrumental
in developing effective and targeted applications of the next
generation of bioelectronic devices and therapies.
Thus,
decoding the language of
electro-modulation is a focus of our research team spearheaded by
Professor Dos Sarbassov at Nazarbayev
University.
We are pleased to be working together on these promising
studies that could have a favorable impact on
human health using physics instead of
drugs."
Dr. Sarbassov
is a prominent expert in cell signaling, who received an intensive
postdoctoral research training at
MIT's Whitehead Institute for
Biomedical Research and worked for many years as a Faculty
Member
of the
Molecular and Cellular Oncology Department at MD Anderson Cancer
Center. He joined Nazarbayev University in 2019 to
contribute to a scientific development of the country of his
origin. In 2020, Dr. Sarbassov became a Director of the National
Laboratory Astana (NLA), a leading research organization at
Nazarbayev University.
Dr. Dos Sarbassov
commented, "Our work with the Electromedical Technologies
is a great collaborative effort of
an
academic
institution with private
industry. This joint focus is on advancing technology by
understanding the mechanisms of electrical communication with cell
physiology. Our primary initial goal
is to
study and
determine how cells react to
alternating electrical fields by analyzing their effects on cell
signaling and by translating how they lead to distinct responses of
cells and tissues."
Matthew Wolfson commented
further, "We seek to utilize the
deciphering of the mechanisms of electrical
signaling on cells in an effort to
provide a solid
foundation in our development of effective treatments of
inflammation, neurodegenerative disorders and opioid addiction.
With the new agreement and program parameters in place, the Company
and the University look forward to commencing the IDE
(Investigational
Device Exemption) process leading to a
submission with the FDA."
About
Nazarbayev University:
Nazarbayev University (NU),
established on the initiative of the first President of the
Republic of Kazakhstan in 2010, is the country's flagship academic
institution with aspirations to become a global-level research
university. This is the first university in Kazakhstan which is
guided by the principles of autonomy and academic freedom. Located
in the capital of Kazakhstan, NU is a research university with
growing international renown combining education, research and
innovation on a state of the art 21st-century campus. NU scholars
conduct research in many fields, and seek to expand human knowledge
through innovation, analysis, and collaboration. Within ten years
since its inception, NU has become a leading research university in
Kazakhstan. NU research is supported by the government of the
Republic of Kazakhstan, local and international organizations, and
is carried out in the Schools, Research Centers and Institutes.
Please visit Nazarbayev University website https://research.nu.edu.kz/en/ to find comprehensive
information on the NU research activities and profiles of faculty
and researchers.
About
Electromedical Technologies
Headquartered in
Scottsdale, Arizona, Electromedical
Technologies, Inc. is a commercial stage, FDA cleared,
bioelectronic medical device manufacturing company initially
focused on the treatment of various chronic, acute, intractable,
and post-operative pain conditions. Through University collaboration
agreements, the Company is working to develop
a comprehensive research program in defining the effects of
electro-modulation on the human body. By studying the impacts of
electrical fields in cell signaling and effects on virus assembly
and immune responses, the Company's goal is
to reduce
pain and improve overall human wellbeing.
The Company's
current FDA cleared product
indications are for chronic acute post traumatic and
post-operative, intractable pain relief. For more information,
please
visit
www.electromedtech.com. Nonhuman preliminary studies
that we are planning to start in the
near
future and their
applications are not
related to our current product in any way and currently not cleared
in the US.
Safe Harbor
Statement
This release
contains forward-looking statements that are based upon current
expectations or beliefs, as well as a number of assumptions about
future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which
they are based are reasonable, we can give no assurance or
guarantee that such expectations and assumptions will prove to have
been correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend," or
"project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous factors and uncertainties,
including but not limited to: adverse economic conditions,
competition, adverse federal, state and local government
regulation, international governmental regulation, inadequate
capital, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and
other specific risks. To the extent that statements in this press
release are not strictly historical, including statements as to
revenue projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
events conditioned on stockholder or other approval, or otherwise
as to future events, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made.
Corporate
Contact:
Electromedical Technologies,
Inc.
Hanover
International
Tel:
1.888.880.7888
email:
ir@electromedtech.com
www.electromedtech.com
ElectroMedical Technolog... (PK) (USOTC:EMED)
Historical Stock Chart
From Apr 2024 to May 2024
ElectroMedical Technolog... (PK) (USOTC:EMED)
Historical Stock Chart
From May 2023 to May 2024
